Tests inhaled salt water to help clear mucus in widened airways
Tests inhaled salt water to clear mucus in adults with bronchiectasis.
Key facts
- Who runs it
- University of North Carolina, Chapel Hill
- Where
- Chapel Hill, United StatesSee the site
- Trial code
- Registry title
- Hypertonic Saline in NCFB
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 20 people, planned
- Started
- 23 Oct 2024
- Planned end
- Jun 2026
- Type of study
- Interventional
- Treatments tested
- 7% Hypertonic Saline via nebulization
- Record updated
- 13 August 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with bronchiectasis not caused by cystic fibrosis. It tests how 7% hypertonic saline by nebulizer affects mucus clearance from the lungs.
- Age
- Adults over 18 years
- Sex
- All sexes can join
- Disease stage
- Bronchiectasis confirmed on a past chest CT scan, in at least 2 lobes, with at least one lobe in the right lung. FEV1 % predicted above 40%. Past bronchiectasis flare-ups needing antibiotics. Chronic cough.
- Earlier treatment
- Must be able to stop hypertonic saline for 2 weeks before the first baseline scan. Cannot use inhaled acetylcysteine or dornase alfa at the same time.
- Biomarker or test result
- Must pass a hypertonic saline tolerability test at screening.
Main reasons for not taking part
- Cystic fibrosis, primary ciliary dyskinesia, chronic aspiration, or bronchiectasis mainly from interstitial lung disease
- Lung flare-up in the past 4 weeks
- Significant coughing up of blood (more than 60 ml) in the past 3 months
- Smoking or vaping anything in the past year, or more than 10 pack-years of cigarettes in a lifetime
- Pregnancy
The registry criteria, word for word
Show all 22 criteriaShow less
Who can take part
- Adults >18 years of age able to provide informed consent
- Diagnosis of bronchiectasis confirmed on prior chest computed tomography (CT), involving at least 2 lobes, with at least one lobe of involvement in the right lung
- Forced expiratory volume in one second (FEV1) % predicted > 40%, inclusive
- History of prior bronchiectasis exacerbations (requiring antibiotics)
- Chronic cough
Who cannot take part
- Unable or unwilling to undergo HS washout period of 2 weeks preceding first baseline MCC scan
- Concomitant inhaled acetylcysteine or dornase alfa use
- Severe asthma, as reflected by need for chronic oral corticosteroids (>10mg/day), asthma biologic therapies, hospitalization for status asthmaticus within the past year, or bronchiectasis felt to have resulted from chronic asthma
- Diagnosis of cystic fibrosis (CF), primary ciliary dyskinesia (PCD), chronic aspiration, or predominantly traction bronchiectasis due to interstitial lung disease (ILD)
- History of intolerance to HS (bronchospasm, hemoptysis)
- History of significant hemoptysis (>60 ml) within the preceding 3 months
- Recent pulmonary exacerbation in preceding 4 weeks
- Chronic supplemental oxygen use at rest
- Significant bronchodilator response (>15% increase in FEV1 or forced vital capacity [FVC]) on pre-post spirometry testing during screening visit
- Failed HS tolerability test (HSTT) at screening, as indicated by:
- Intolerable symptoms after HS administration
- Decline in FEV1 % predicted by >20% when measured 15 min after HS administration
- Decline in FEV1 % predicted between 10-20% when measured at 15 min that does not recover to within 10% of baseline without intervention 1 hour post HS test dose
- Smoking/vaping, any substance within the past year, or >10 pack-years of cigarette use over their lifetime
- More than 2 chest CTs in the past year or a combination of procedures believed to have exposed the lungs to >150 millisieverts (mSv)
- Current/recent participation in other interventional studies for NCFB, allowing for appropriate wash-out time
- Pregnancy
Where in United States
- University of North Carolina at Chapel HillChapel Hill, United StatesContact: Katherine A. Despotes, MDTaking people
About the trial
What the trial wants to find out
The purpose of this single arm clinical trial is to evaluate the effects of 7% hypertonic saline (HS) delivered by nebulizer on clearance of mucus from the lungs in people with bronchiectasis (dilated airways) not due to cystic fibrosis. Mucociliary clearance (MCC) to measure the rate at which a person's lungs can clear inhaled particles will be assessed at baseline, and after acute (single dose) HS treatment, as well as after two weeks of treatment with HS.
Read full original descriptionShow less
The study has two main questions:
1. Evaluate the repeatability MCC measures in people with non-CF bronchiectasis 2. Compare MCC at baseline (before treatment with HS), after a single dose of HS (acute effect of HS), and after two weeks of treatment with HS twice a day (sustained effect of HS).
Participants will participate in up to 5 study visits if completing both Aim 1 and Aim 2: 1 screening/enrollment visit, 2 baseline visits (1 baseline visit if only participating in Aim 2), 1 visit during which first dose of HS would be administered and assessed, and 1 visit after 2 weeks of treatment with HS.
The group in the trial
- Single arm treatment group with 7% HSTreatment being tested
All study participants will receive 7% HS by nebulizer twice a day for two weeks as part of airway clearance.
Treatment: 7% Hypertonic Saline via nebulization
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Effect of Hypertonic Saline on Mucociliary Clearance in Non-CF Bronchiectasis
- Plain-language title
- Tests inhaled salt water to help clear mucus in widened airwaysGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 13 August 2025